medigraphic.com
ISSN 1561-3070 (Electronic)

2015, Number 1

<< Back

Rev Cub Oftal 2015; 28 (1)

Vogt-Koyanagi-Harada disease and visual rehabilitation

Quintero BM, Vilches LDC, Bueno AY, Rodríguez MS, Perea RCA, Paz LM

Language: Spanish
References: 18
Page: 146-151
PDF size: 83.29 Kb.


ABSTRACT

Vogt-Koyanagi-Harada (VKH) is a rare, multisystemic, allegedly autoimmune disease of unknown etiology. It is characterized by chronic bilateral granulomatous and diffuse panuveitis, accompanied by tegumentary, neurological and hearing impairments that often affect the non-Caucasians and usually women. It usually occurs in the 20-25 years age group and its incidence varies with the geographic location. It is estimated that 25% of the patients with this disease are legally blind, the other 25% may have low vision and 50% present with visual acuity over 20/50. There is a 50 years-old patient with a history of Vogt - Koyanagi - Harada disease for 8 years. He had been treated with systemic steroid anti-inflammatory drugs and immunosuppressive therapy as well as supporting therapy with topical and cycloplegic steroid anti-inflammatories. The patient had gone to the low vision service looking for rehabilitation. He was performed a complete eye examination, supplementary studies and he was finally rehabilitated through the use of optical and non-optical aids in order to maximize his remaining vision.


REFERENCES

  1. American Academy of Ophthalmology. Intraocular inflammation and uveitis. EE.UU.: American Academy of Ophthalmology; 2008.

  2. Onho-Matsui K, Horie S, Mochizuki M. Primary Stromal Choroiditis. Vogt-Koyanagi- Harada (VKH) Disease. En: Gupta A, Gupta V, Herbort CP, Khairallah M. Uveitis text and imaging. New Delhi: Jaypee Brothers; 2009. p. 529-39.

  3. Tesavibul N. Vogt-Koyanagi-Harada Syndrome. En: Foster CS, Vitale AT. Diagnosis and treatment of uveitis. Philadelphia: Saunders; 2001. p. 748-54.

  4. Sukavatcharin S, Tsai JH, Rao NA. Vogt-Koyanagi-Harada disease in Hispanic patients. Int Ophthalmol. 2007;27(2-3):143-8.

  5. Goto H, Mochizuki M, Yamaki K, Kotake S, Usui M, Ohno S. Epidemiological survey of intraocular inflammation in Japan. Jap J Ophthalmol. 2007;51(1):41-4.

  6. Nussenblatt RB. Vogt-Koyanagi-Harada Syndrome. En: Nussenblatt RB, Whitcup SM. Uveitis: fundamental and clinical practice. Philadelphia: Mosby; 2004. p. 324-36.

  7. Kiyomoto C, Imaizumi M, Kimoto K, Abe H, Nakano S, Nakatsuka K. Vogt– Koyanagi– Harada disease in elderly Japanese patients. Int Ophthalmol 2007; 27:149-53.

  8. Perente I, Utine CA, Cakir H, Kaya V, Tutkun IT, Yilmaz OF . Management of ocular complications of Vogt-Koyanagi-Harada syndrome. Int Ophthalmol. 2009;29(1):33-7.

  9. Fardeau C, Tran TH, Gharbi B, Cassoux N, Bodaghi B, Le HP. Retinal fluorescein and indocyanine green angiography and optical coherence tomography in successive stages of Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2007;27(2-3):163-72.

  10. Yamamura K, Mori K, Hieda O, Kinoshita S. Anterior segment optical coherence tomography findings of acute angle closure glaucoma in Vogt-Koyanagi-Harada disease. Jap J OphthalmoL. 2008;52(3):231-2.

  11. Tsai JH, Sukavatcharin S, Rao NA. Utility of lumbar puncture in diagnosis of Vogt- Koyanagi-Harada disease. Int Ophthalmol. 2007;27(2-3):189-94.

  12. Ya-Ling Guo YL, Du Y, He JF. Correlation between sunset glow fundus and initial dosage of corticosteroid in patients with Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2009;147(5):946.

  13. Liu X, Yang P, Lin X, Ren X, Zhou H, Huang X, et al. Inhibitory effect of cyclosporin A and corticosteroids on the production of IFN-y and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome. Clin Inmunol. 2009;131(2):333-42.

  14. da Silva FT1, Damico FM, Marin ML, Goldberg AC, Hirata CE, Takiuti PH, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: considerations on the different disease categories. Am J Ophthalmol. 2009;147(2):339-45.

  15. Tugal-Tutkun I, Ozyazgan Y, Akova YA, Sullu Y, Akyol N, Soylu M, et al. The spectrum of Vogt-Koyanagi-Harada disease in Turkey. Int Ophthalmol. 2007;27(23):117-23.

  16. Barañano Gl. Atención en baja visión. Madrid: ONCE; 2008.

  17. OMS. Visión 2020. El derecho a la visión. Iniciativa mundial para la eliminación de la ceguera evitable. IAPB, 2006-2011; 2008.

  18. Ramos AE. Toxoplasmosis ocular y rehabilitación visual. Presentación de un caso. Revista Habanera de Ciencias Médicas. 2013;12(1):48-56.




2020     |     www.medigraphic.com